845.475.4158

CBD (Pure) Extra Strength 200mg 1oz Bottle

Availability: In stock

$35.95

Helps reduce inflammation, supports nerve health and helps manage stress and mood swings.
OR

CBD (Pure) Extra Strength 200mg 1oz Bottle

Details

Pure CBD (cannabidiol) Extra Strength in liquid form is absorbed by the body quickly to provide effective and noticeable relief from stress. The drops are easy to take with a pleasant natural mint taste.

Pure CBD Extra Strength provides gold filtered CBD emulsified in organic hemp seed oil.

Benefits include:

  • Mood support and stress management through balancing of the body's natural endocannabinoid system which helps to support adapting to stress and the physiological effects of stress.
  • Neurological Support:Research indicates that cannabidiol helps to protect the nervous system in patients with multiple sclerosis and other neurological conditions such as Parkinson's, Lyme disease, epilepsy, and spinal cord injury. Cannabidiol accomplishes this by helping to moderate over-stimulation of the inflammatory response in muscles and nerves.
  • Inflammation Reduction: Cannabinoids regulate the body's inflammatory response through several mechanisms, including suppressing production of pro-inflammatory biochemicals in the body, suppressing overactive immune cells, and enhanced T cell activity.

Pure CBD Extra Strength is produced under strict GMP manufacturing controls in conformance with guidelines for dietary supplements set forth in USP XXVII.

Related Research

RESEARCH SUPPORT FOR MOOD CONDITIONS

In humans, the stress response initiates hypothalamic-pituitary-adrenal (HPA) axis activation, changes in central nervous system activity, neuroimmune alternations, as well as other physiological changes. While the acute stress response is essential to survival, chronic, untreated stress can contribute to a variety of other serious conditions.

Stress and anxiety can go hand-in-hand, with the terms often used interchangeably. They are, however, quite different. Stress, unlike anxiety, is the response to a threat or the pressures of daily life. Anxiety is a possible adverse reaction to stress, typically manifesting as fear or apprehension, and can present with physical symptoms such as racing heart, pain, shortness of breath, and/or dizziness. Generally, stress subsides after the stressor is removed, while anxiety symptoms can persist for six months or longer.

The endocannabinoid system serves to constrain HPA axis activity during times of stress. The involvement of signaling molecules (cytokines and chemokines) in the endocannabinoid-mediated stress response are of importance when considering therapeutic strategies. Animal studies have investigated endocannabinoid signaling under conditions of repeated stress and have demonstrated that disrupted signaling may be associated with decreased ability to adapt to chronic stress. In animals, CBD has been shown, via mediation of the endocannabinoid system, to promote adaptation to stress and its physiological effects.

1. Resstel LB, Tavares RF, Lisboa SF, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol. 2009;156:181-188.
2. Gorzalka BB, Hill MN, Hillard CJ. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorder. Neurosci Biobehav Rev 2008;32:1152-1160.
3. Hill MN, McLaughlin RJ, Bingham B, et al. Endogenous cannabinoid signaling is essential for stress adaptation. PNAS 2010;107:9406-9411
4. Finn DP. Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiol 2010;215:629-646.
5. Lee JL, Bertoglio LJ, Guimarães FS, Stevenson CW. Cannabidiol regulation of emotion and emotional processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol. 2017 Mar 7. [Epub ahead of print]
6. Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J 2016;20:108-111.
7. Campos AC, Ferreira FR, Guimarães FS. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res 2012;46:1501-1510.
8. Stanley Medical Research Institute, Coordinating Centre for Clinical Trials Cologne. University of Cologne. A clinical trial on the antipsychotic properties of cannabidiol. ClinicalTrials.gov.http://ClinicalTrials.gov/show/NCT00309413.

RESEARCH SUPPORT FOR INFLAMMATORY CONDITIONS

The use of Cannabis for pain dates back thousands of years and more recently, significant research has evaluated the benefit of CBD and other cannabinoids for supporting those with various types of inflammation. Cannabinoids show promise as a new class of inflammation-modulating agents, via their action on cannabinoid receptors in the endocannabinoid system. Cannabinoids modulate the inflammatory response via multiple pathways, including suppression of overactive immune cells, suppression of pro-inflammatory cytokines and chemokines at inflammatory sites, and enhanced T cell activity. Many significant medical conditions are a result of, or characterized by, chronic inflammation. Researchers are constantly exploring new agents to help alleviate the symptoms of chronic pain. Emerging cannabinoid research is showing promise for supporting individuals with chronic pain of various origins.

1. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210-220.
2. GW Pharmaceuticals Ltd. A study to evaluate the effects of cannabis based medicine in patients with pain of neurological origin. ClinicalTrials.gov.http://ClinicalTrials.gov/show/NCT01606176
3. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260:984-997.
4. Wilsey B, Marcotte T, Deutsch R, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14:136-148.
5. Center for Medicinal Cannabis Research. Efficacy of inhaled cannabis in diabetic painful peripheral neuropathy. ClinicalTrials.gov.http://ClinicalTrials.gov/show/NCT00781001.
6. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33:128-130.
7. De Fillipis D, Esposito G, Cirillo C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS ONE 2011;6:1-8.
8. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45:50-52.
9. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164-173.
10. Rog DJ, Nurmikko T, Young C, Sarantis NS. Randomized controlled trial of sativex, a cannabis based medicine (CBM), in central neuropathic pain due to multiple sclerosis, followed by an open-label extension. Neurology. 2006;66:A31.
11. GW Pharma Ltd. A double blind, randomised, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy. EU Clinical Trials Register.https://www.clinicaltrialsregister.eu/ctr-search/search?

RESEARCH SUPPORT FOR NEUROLOGICAL CONDITIONS

Over 400,000 people in the United States suffer from multiple sclerosis (MS), with approximately 200 new cases diagnosed each week. Diagnosis usually occurs between the ages of 20 – 40, but MS also affects children and the aged. MS is a chronic, progressive disease involving damage to the sheaths of nerve cells in the brain and spinal cord. Symptoms vary, but may include impairment of speech and of muscular coordination, numbness, nerve pain, muscle spasticity, blurred vision, and severe fatigue. Recent research on cannabidiol shows it to be neuroprotective in those with MS and other neurological conditions such as Parkinson’s disease and spinal cord injury. It is thought to exert this effect by regulating inflammation in the nerves and muscles.

1. Zajicek J, Fox P, Sanders H, et al; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517-1526.
2. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664-1669.
3. Pooyania S, Ethans K, Szturm et al. A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil. 2010;91:703-707.
4. GW Pharmaceuticals Ltd. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. ClinicalTrials.gov.http://ClinicalTrials.gov/show/NCT01606202
5. Corey-Bloom J, Wolfson J, Anthony et al. Short-term effects off medicinal cannabis on spasticity in multiple sclerosis. Neurology. 2008;70:A86-A87.
6. Vzney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10:417-424.
7. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451-459.
8. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? a double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434-441.

RESEARCH SUPPORT FOR ONCOLOGIC CONDITIONS

Cannabinoids have been shown to possess anticarcinogenic effects and are known to interfere with all stages of tumor formation and metastasis. Emerging research on the efficacy of CBD in modulating the different stages of tumorigenesis in several types of cancer highlights the importance of continuing to explore CBD/CBD analogues as alternative therapeutic agents. Unfortunately, due to current regulatory restrictions, the use of cannabinoids as direct therapeutic agents has been limited.

Currently, the main use of cannabinoids in cancer patients is for symptom management. The most researched and established roles for cannabinoid therapies include pain and chemotherapy-induced nausea and vomiting. The palliative use of cannabinoid therapies may be of benefit in improving quality of life and compliance with chemotherapy and radiation therapy in cancer patients.

1. Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer. 1983;48:657-663.
2. Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev.1982;9:SB25-SB33.
3. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47:166-173
4. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39:167-17
5. Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs placebo in cancer chemotherapy. Cancer Treat Rev.1982;9:S39-S44.
6. Hutcheon AW, Palmer JB, Soukop M, et al. A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol. 1983;19:1087-1090.
7. Duran M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70:656-663.

Macular Degeneration
Perhaps the potent antioxidant properties of the cannabinoids may be beneficial in AMD, offering a possible alternative to established antioxidant supplements. Age-Related Eye Disease Study Research Group. A randomised, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 2001;119:1417.

Cannabinoids have been shown to inhibit angiogenesis, leading to a decrease in the expression of proangiogenic factors such as VEGF. Casanova ML, Blázques C, Martinez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoids receptors. J Clin Inverst 2003;111:43–50. Evidence suggests that VEGF plays a major part in the development of choroidal neovascularisation in AMD, and clinical trials using anti-VEGF therapies are being conducted. The Eye Tech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143–52.

Login and then Write Your Own Review

You're reviewing: CBD (Pure) Extra Strength 200mg 1oz Bottle

How do you rate this product? *

  1 star 2 stars 3 stars 4 stars 5 stars
Quality